204 related articles for article (PubMed ID: 27830347)
1. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
[TBL] [Abstract][Full Text] [Related]
2. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
3. [Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].
Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(10):1111-8. PubMed ID: 23037696
[TBL] [Abstract][Full Text] [Related]
4. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
5. [Mitochondrial DDS Opens Innovative Pharmaceutics].
Yamada Y
Yakugaku Zasshi; 2016; 136(1):55-62. PubMed ID: 26725668
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
Yamada Y; Harashima H
Methods Mol Biol; 2021; 2275():227-245. PubMed ID: 34118041
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.
Yamada Y; Nakamura K; Abe J; Hyodo M; Haga S; Ozaki M; Harashima H
J Control Release; 2015 Sep; 213():86-95. PubMed ID: 26160304
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.
Yamada Y; Nakamura K; Furukawa R; Kawamura E; Moriwaki T; Matsumoto K; Okuda K; Shindo M; Harashima H
J Pharm Sci; 2013 Mar; 102(3):1008-15. PubMed ID: 23315986
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
12. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion.
Yamada Y; Akita H; Kamiya H; Kogure K; Yamamoto T; Shinohara Y; Yamashita K; Kobayashi H; Kikuchi H; Harashima H
Biochim Biophys Acta; 2008 Feb; 1778(2):423-32. PubMed ID: 18054323
[TBL] [Abstract][Full Text] [Related]
13. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
Yamada Y; Munechika R; Satrialdi ; Kubota F; Sato Y; Sakurai Y; Harashima H
J Pharm Sci; 2020 Aug; 109(8):2493-2500. PubMed ID: 32376272
[TBL] [Abstract][Full Text] [Related]
15. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.
Yamada Y; Fukuda Y; Harashima H
Mitochondrion; 2015 Sep; 24():50-5. PubMed ID: 26188112
[TBL] [Abstract][Full Text] [Related]
16. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
Furukawa R; Yamada Y; Kawamura E; Harashima H
Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
[TBL] [Abstract][Full Text] [Related]
18. Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
Kawamura E; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():178-188. PubMed ID: 31472283
[TBL] [Abstract][Full Text] [Related]
19. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
Yamada Y; Harashima H
Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
[TBL] [Abstract][Full Text] [Related]
20. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
Furukawa R; Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
